An Exploratory, Open-label Study to Evaluate the Safety of PRX-112 and Pharmacokinetics of Oral prGCD (Plant Recombinant Human Glucocerebrosidase) in Gaucher Patients

Trial Profile

An Exploratory, Open-label Study to Evaluate the Safety of PRX-112 and Pharmacokinetics of Oral prGCD (Plant Recombinant Human Glucocerebrosidase) in Gaucher Patients

Completed
Phase of Trial: Phase I

Latest Information Update: 04 Jun 2014

At a glance

  • Drugs Taliglucerase alfa (Primary)
  • Indications Gaucher's disease
  • Focus Adverse reactions
  • Sponsors Protalix Biotherapeutics
  • Most Recent Events

    • 04 Apr 2014 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.
    • 13 Jan 2014 Phase I results, including results from patients with low platelet counts, will be presented at the Lysosomal Storage Disease Network WORLD Symposium (LDN WORLD) in February 2014, according to a Protalix media release.
    • 23 Oct 2013 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top